Moreover, Pem is currently under investigation in an open-label, phase II, monotherapy study (NCT05267106 – FIGHT 209) for recurrent GBM or other primary CNS tumours with an activating FGFR1-3 mutation or fusion/rearrangement [63]. Here, FGFR1 is linked to glioblastoma.